Amedisys Board of Directors Authorizes $100 million Stock Repurchase Program
December 23, 2020 at 16:15 PM EST
BATON ROUGE, La., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), America’s leading independent home health, hospice and personal care company, today announced that its Board of Directors has authorized a stock repurchase program, under which the Company may repurchase up to $100 million of its outstanding common stock through December 31, 2021.
Scott Ginn, Chief Financial Officer, stated, “Given our strong cashflow and low leverage, we feel it is prudent to have authorization to buy-back shares throughout the course of the year, including shares granted under the Company’s Omnibus Incentive Plan as they vest in 2021. This will become a recurring part of our capital deployment strategy; however, our first priority is and will continue to be accretive acquisitions in both Home Health and Hospice.”
Under the stock repurchase program, the Company may repurchase its common stock from time to time, in amounts, at prices, and at such times as the Company deems appropriate, subject to market conditions and other considerations and in accordance with applicable federal securities laws and other legal requirements. The Company's repurchases may be executed using open market purchases, unsolicited or solicited privately negotiated transactions, an accelerated stock repurchase program, and/or a 10b5-1 trading plan.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.